PRVA · Privia Health Group, Inc. · Insider Trading
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-09-01 | Ernest Opella Finley |
Director |
Award↑
Filing footnotes — Common Stock, $0.01 par value per share (Direct)
Represents restricted stock units granted under the Issuer's 2021 Omnibus Incentive Plan that will become fully vested on the day immediately preceding the date of Company's 2027 Annual Meeting of Stockholders. |
Common Stock, $0.01 par value per share
|
6,350 |
| 2026-07-09 | Mountcastle David |
EVP & Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock, par value $0.01 per share (Direct)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.50 to $27.80 per share. The reporting person undertakes to provide to Privia Health Group, Inc., any security holder of Privia Health Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
Common Stock, par value $0.01 per share
|
21,275 |
| 2026-07-07 | Mountcastle David |
EVP & Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock, par value $0.01 per share (Direct)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.55 to $27.58 per share. The reporting person undertakes to provide to Privia Health Group, Inc., any security holder of Privia Health Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
Common Stock, par value $0.01 per share
|
600 |
| 2026-07-06 | Morris Matthew Shawn |
Director |
Convert↓
Filing footnotes — Stock Option (Right to Purchase) (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. All of the stock options are fully vested and exercisable. |
Stock Option (Right to Purchase)
|
53,722 |
| 2026-07-06 | Morris Matthew Shawn |
Director |
Sell↓
Filing footnotes — Common Stock, par value $0.01 per share (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.09 to $27.39 per share. The reporting person undertakes to provide to Privia Health Group, Inc., any security holder of Privia Health Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Reflects the forfeiture of 8,463 unvested restricted stock units granted on May 20, 2026 under the Issuer's 2021 Omnibus Incentive Plan. |
Common Stock, par value $0.01 per share
|
53,722 |
| 2026-07-06 | Morris Matthew Shawn |
Director |
Convert↑
Filing footnotes — Common Stock, par value $0.01 per share (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. |
Common Stock, par value $0.01 per share
|
53,722 |
| 2026-07-02 | Morris Matthew Shawn |
Director |
Convert↓
Filing footnotes — Stock Option (Right to Purchase) (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. All of the stock options are fully vested and exercisable. |
Stock Option (Right to Purchase)
|
59,037 |
| 2026-07-02 | Morris Matthew Shawn |
Director |
Convert↑
Filing footnotes — Common Stock, par value $0.01 per share (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. |
Common Stock, par value $0.01 per share
|
59,037 |
| 2026-07-02 | Morris Matthew Shawn |
Director |
Sell↓
Filing footnotes — Common Stock, par value $0.01 per share (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.90 to $27.53 per share. The reporting person undertakes to provide to Privia Health Group, Inc., any security holder of Privia Health Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
Common Stock, par value $0.01 per share
|
59,037 |
| 2026-07-02 | Mountcastle David |
EVP & Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock, par value $0.01 per share (Direct)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.50 to $27.51 per share. The reporting person undertakes to provide to Privia Health Group, Inc., any security holder of Privia Health Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
Common Stock, par value $0.01 per share
|
24,734 |
| 2026-07-01 | Morris Matthew Shawn |
Director |
Sell↓
Filing footnotes — Common Stock, par value $0.01 per share (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.81 to $27.09 per share. The reporting person undertakes to provide to Privia Health Group, Inc., any security holder of Privia Health Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
Common Stock, par value $0.01 per share
|
37,041 |
| 2026-07-01 | Morris Matthew Shawn |
Director |
Convert↑
Filing footnotes — Common Stock, par value $0.01 per share (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. |
Common Stock, par value $0.01 per share
|
82,675 |
| 2026-07-01 | Morris Matthew Shawn |
Director |
Convert↓
Filing footnotes — Stock Option (Right to Purchase) (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. All of the stock options are fully vested and exercisable. |
Stock Option (Right to Purchase)
|
82,675 |
| 2026-07-01 | Morris Matthew Shawn |
Director |
Sell↓
Filing footnotes — Common Stock, par value $0.01 per share (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.81 to $26.80 per share. The reporting person undertakes to provide to Privia Health Group, Inc., any security holder of Privia Health Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
Common Stock, par value $0.01 per share
|
45,634 |
| 2026-06-30 | Morris Matthew Shawn |
Director |
Sell↓
Filing footnotes — Common Stock, par value $0.01 per share (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.15 to $26.03 per share. The reporting person undertakes to provide to Privia Health Group, Inc., any security holder of Privia Health Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
Common Stock, par value $0.01 per share
|
52,823 |
| 2026-06-30 | Morris Matthew Shawn |
Director |
Convert↑
Filing footnotes — Common Stock, par value $0.01 per share (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. |
Common Stock, par value $0.01 per share
|
52,823 |
| 2026-06-30 | Morris Matthew Shawn |
Director |
Convert↓
Filing footnotes — Stock Option (Right to Purchase) (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. All of the stock options are fully vested and exercisable. |
Stock Option (Right to Purchase)
|
52,823 |
| 2026-06-29 | Morris Matthew Shawn |
Director |
Convert↑
Filing footnotes — Common Stock, par value $0.01 per share (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. |
Common Stock, par value $0.01 per share
|
63,212 |
| 2026-06-29 | Morris Matthew Shawn |
Director |
Convert↓
Filing footnotes — Stock Option (Right to Purchase) (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. All of the stock options are fully vested and exercisable. |
Stock Option (Right to Purchase)
|
63,212 |
| 2026-06-29 | Morris Matthew Shawn |
Director |
Sell↓
Filing footnotes — Common Stock, par value $0.01 per share (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.14 to $25.67 per share. The reporting person undertakes to provide to Privia Health Group, Inc., any security holder of Privia Health Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
Common Stock, par value $0.01 per share
|
63,212 |
| 2026-06-26 | Morris Matthew Shawn |
Director |
Convert↑
Filing footnotes — Common Stock, par value $0.01 per share (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. |
Common Stock, par value $0.01 per share
|
88,110 |
| 2026-06-26 | Mountcastle David |
EVP & Chief Financial Officer |
Convert↑
Filing footnotes — Common Stock, par value $0.01 per share (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. |
Common Stock, par value $0.01 per share
|
17,196 |
| 2026-06-26 | Mountcastle David |
EVP & Chief Financial Officer |
Convert↓
Filing footnotes — Stock Option (Right to Purchase) (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. All of the stock options are fully vested and exercisable. |
Stock Option (Right to Purchase)
|
8,897 |
| 2026-06-26 | Mountcastle David |
EVP & Chief Financial Officer |
Convert↓
Filing footnotes — Stock Option (Right to Purchase) (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. All of the stock options are fully vested and exercisable. |
Stock Option (Right to Purchase)
|
5,962 |
| 2026-06-26 | Mountcastle David |
EVP & Chief Financial Officer |
Convert↓
Filing footnotes — Stock Option (Right to Purchase) (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. All of the stock options are fully vested and exercisable. |
Stock Option (Right to Purchase)
|
1,001 |
| 2026-06-26 | Morris Matthew Shawn |
Director |
Sell↓
Filing footnotes — Common Stock, par value $0.01 per share (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.98 to $25.70 per share. The reporting person undertakes to provide to Privia Health Group, Inc., any security holder of Privia Health Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
Common Stock, par value $0.01 per share
|
88,110 |
| 2026-06-26 | Mountcastle David |
EVP & Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock, par value $0.01 per share (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.68 per share. The reporting person undertakes to provide to Privia Health Group, Inc., any security holder of Privia Health Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
Common Stock, par value $0.01 per share
|
17,196 |
| 2026-06-26 | Morris Matthew Shawn |
Director |
Convert↓
Filing footnotes — Stock Option (Right to Purchase) (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. All of the stock options are fully vested and exercisable. |
Stock Option (Right to Purchase)
|
88,110 |
| 2026-06-26 | Mountcastle David |
EVP & Chief Financial Officer |
Convert↓
Filing footnotes — Stock Option (Right to Purchase) (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. All of the stock options are fully vested and exercisable. |
Stock Option (Right to Purchase)
|
1,336 |
| 2026-05-20 | Morris Matthew Shawn |
Director |
Award↑
Filing footnotes — Common Stock, par value $0.01 per share (Direct)
On May 20, 2026, the reporting person received 8,463 restricted stock units under the Issuer's 2021 Omnibus Incentive Plan. The restricted stock units will vest on the earlier of (i) the day immediately preceding the Company's 2027 annual meeting of stockholders and (ii) the first anniversary of the date of the grant. |
Common Stock, par value $0.01 per share
|
8,463 |
| 2026-05-20 | Kimmet Pamela O |
Director |
Award↑
Filing footnotes — Common Stock, par value $0.01 per share (Direct)
On May 20, 2026, the reporting person received 8,463 restricted stock units under the Issuer's 2021 Omnibus Incentive Plan. The restricted stock units will vest on the earlier of (i) the day immediately preceding the Company's 2027 annual meeting of stockholders and (ii) the first anniversary of the date of the grant. |
Common Stock, par value $0.01 per share
|
8,463 |
| 2026-05-20 | McCarthy Thomas A |
Director |
Award↑
Filing footnotes — Common Stock, $0.01 par value per share (Direct)
On May 20, 2026, the reporting person received 8,463 restricted stock units under the Issuer's 2021 Omnibus Incentive Plan. The restricted stock units will vest on the earlier of (i) the day immediately preceding the Company's 2027 annual meeting of stockholders and (ii) the first anniversary of the date of the grant. |
Common Stock, $0.01 par value per share
|
8,463 |
| 2026-05-20 | SOISTMAN FRANCIS S JR |
Director |
Award↑
Filing footnotes — Common Stock, $0.01 par value per share (Direct)
On May 20, 2026, the reporting person received 8,463 restricted stock units under the Issuer's 2021 Omnibus Incentive Plan. The restricted stock units will vest on the earlier of (i) the day immediately preceding the Company's 2027 annual meeting of stockholders and (ii) the first anniversary of the date of the grant. |
Common Stock, $0.01 par value per share
|
8,463 |
| 2026-05-20 | BERBERIAN LANCE |
Director |
Award↑
Filing footnotes — Common Stock, $0.01 par value per share (Direct)
On May 20, 2026, the reporting person received 8,463 restricted stock units under the Issuer's 2021 Omnibus Incentive Plan. The restricted stock units will vest on the earlier of (i) the day immediately preceding the Company's 2027 annual meeting of stockholders and (ii) the first anniversary of the date of the grant. |
Common Stock, $0.01 par value per share
|
8,463 |
| 2026-05-20 | COCOZZA NANCY G |
Director |
Award↑
Filing footnotes — Common Stock, $0.01 par value per share (Direct)
On May 20, 2026, the reporting person received 8,463 restricted stock units under the Issuer's 2021 Omnibus Incentive Plan. The restricted stock units will vest on the earlier of (i) the day immediately preceding the Company's 2027 annual meeting of stockholders and (ii) the first anniversary of the date of the grant. |
Common Stock, $0.01 par value per share
|
8,463 |
| 2026-05-20 | KING DAVID P |
Director |
Award↑
Filing footnotes — Common Stock, $0.01 par value per share (Direct)
On May 20, 2026, the reporting person received 8,463 restricted stock units under the Issuer's 2021 Omnibus Incentive Plan. The restricted stock units will vest on the earlier of (i) the day immediately preceding the Company's 2027 annual meeting of stockholders and (ii) the first anniversary of the date of the grant. |
Common Stock, $0.01 par value per share
|
8,463 |
| 2026-05-20 | Ryu Jaewon |
Director |
Award↑
Filing footnotes — Common Stock, $0.01 par value per share (Direct)
On May 20, 2026, the reporting person received 8,463 restricted stock units under the Issuer's 2021 Omnibus Incentive Plan. The restricted stock units will vest on the earlier of (i) the day immediately preceding the Company's 2027 annual meeting of stockholders and (ii) the first anniversary of the date of the grant. |
Common Stock, $0.01 par value per share
|
8,463 |
| 2026-05-12 | Mehrotra Parth |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Common Stock, $0.01 par value per share (Direct)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person |
Common Stock, $0.01 par value per share
|
15,647 |
| 2026-05-11 | Mehrotra Parth |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Common Stock, $0.01 par value per share (Direct)
Certain of the sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and certain of the sales represent a nondiscretionary sale of shares required to be sold by the Reporting Person pursuant to "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.28 to $23.10 per share. The reporting person undertakes to provide to Privia Health Group, Inc., any security holder of Privia Health Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
Common Stock, $0.01 par value per share
|
105,439 |
| 2026-05-11 | Mountcastle David |
EVP & Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock, par value $0.01 per share (Direct)
The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the Reporting Person pursuant to "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units. |
Common Stock, par value $0.01 per share
|
3,385 |
| 2026-05-04 | Morris Matthew Shawn |
Director |
Sell↓
Filing footnotes — Common Stock, par value $0.01 per share (Direct)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.95 to $24.98 per share. The reporting person undertakes to provide to Privia Health Group, Inc., any security holder of Privia Health Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
Common Stock, par value $0.01 per share
|
1,017 |
| 2026-05-04 | Mountcastle David |
EVP & Chief Financial Officer |
Convert↓
Filing footnotes — Stock Option (Right to Purchase) (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. All of the stock options are fully vested and exercisable. |
Stock Option (Right to Purchase)
|
202 |
| 2026-05-04 | Mountcastle David |
EVP & Chief Financial Officer |
Convert↓
Filing footnotes — Stock Option (Right to Purchase) (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. All of the stock options are fully vested and exercisable. |
Stock Option (Right to Purchase)
|
52 |
| 2026-05-04 | Mountcastle David |
EVP & Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock, par value $0.01 per share (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. |
Common Stock, par value $0.01 per share
|
1,206 |
| 2026-05-04 | Mountcastle David |
EVP & Chief Financial Officer |
Convert↓
Filing footnotes — Stock Option (Right to Purchase) (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. All of the stock options are fully vested and exercisable. |
Stock Option (Right to Purchase)
|
592 |
| 2026-05-04 | Mountcastle David |
EVP & Chief Financial Officer |
Convert↓
Filing footnotes — Stock Option (Right to Purchase) (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. All of the stock options are fully vested and exercisable. |
Stock Option (Right to Purchase)
|
360 |
| 2026-05-04 | Morris Matthew Shawn |
Director |
Convert↑
Filing footnotes — Common Stock, par value $0.01 per share (Direct)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. |
Common Stock, par value $0.01 per share
|
1,017 |
| 2026-05-04 | Morris Matthew Shawn |
Director |
Convert↓
Filing footnotes — Stock Option (Right to Purchase) (Direct)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. All stock options are fully vested and exercisable. |
Stock Option (Right to Purchase)
|
1,017 |
| 2026-05-04 | Mountcastle David |
EVP & Chief Financial Officer |
Convert↑
Filing footnotes — Common Stock, par value $0.01 per share (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. |
Common Stock, par value $0.01 per share
|
1,206 |
| 2026-05-01 | Mountcastle David |
EVP & Chief Financial Officer |
Convert↓
Filing footnotes — Stock Option (Right to Purchase) (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. All of the stock options are fully vested and exercisable. |
Stock Option (Right to Purchase)
|
2,331 |